FindTrial
Sign In

Study on the mechanism of CDC73/RNF20-mediated H2B monoubiquitination modification to alleviate paclitaxel resistance in esophageal cancer

Study on the mechanism of CDC73/RNF20-mediated H2B monoubiquitination modification to alleviate paclitaxel resistance in esophageal cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2024000655
Enrollment
Unknown
Registered
2024-11-05
Start date
2025-01-01
Completion date
Unknown
Last updated
2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

esophageal cancer

Interventions

No Chinese medicine group:The non-TCM group was not treated with Qi Diaphragm.
Qidiaphan group:The Qidiaphan group was given 1 dose per day, divided into morning and evening, 14 days as a course of treatment, a total of 3 courses of treatment.

Sponsors

Ningbo Medical Center Li Huili Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients with a clinical diagnosis of esophageal cancer

Exclusion criteria

Exclusion criteria: 1: 1) Severe cardiovascular disease that cannot tolerate laparoscopic surgery 2: 2) acute inflammatory phase 3: 3) Preoperative suspicion of other malignant tumors or distant metastases of malignant tumors

Design outcomes

Primary

MeasureTime frame
The expression level of CDC73 in blood samples of esophageal cancer patients was detected by RT-qPCR;—

Countries

CHINA

Contacts

Public Contactsongjie

Ningbo Medical Center Li Huili Hospital

349809596@qq.com13566391189

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026